Medicare And Medicaid Fraud
Definition of 'Medicare And Medicaid Fraud'Illegal practices aimed at getting unfairly high payouts from government-funded healthcare programs. There are many types of Medicare and Medicaid fraud, including billing for services that weren't provided (phantom billing, upcoding), performing unnecessary tests or giving unnecessary referrals (pingponging), charging separately for services that are usually charged at a package rate (unbundling) and many more. |
|
Investopedia explains 'Medicare And Medicaid Fraud'Medicare and Medicaid fraud are a multi-billion dollar drain on a system that is already expensive to maintain. There are external auditors who are responsible for reviewing suspicious claim patterns, but the sheer volume means that many frauds can go undetected for years. |
Related Definitions
Articles Of Interest
-
Services That Health Insurers Often Decline
Learning how to navigate health insurance pitfalls will make you a more educated healthcare consumer. -
What's The Difference Between Medicare And Medicaid?
One program is for the poor; the other is for the elderly. Learn which is which. -
What Does Medicare Cover?
Don't assume you're insured. Find out what you can expect from this healthcare program. -
Fighting The High Costs Of Healthcare
If your employer is cutting medical benefits, a health savings account may be right for you. -
Stop Scams In Their Tracks
Find out how to protect yourself and your loved ones from financial fraudsters. -
Valeant Eyes Bausch & Lomb
Canadian pharmaceutical company Valeant has made a name for itself through acquisitions. On May 27 it announced that it was buying Bausch & Lomb for $8.7 billion making it a global leader in ... -
Medtronic Still Reporting Weak Growth, But A Relatively Rare Bargain
Medtronic continues to suffer with weak core markets, but business seems to be getting slowly better and valuation is not demanding -
Roche, Reloaded
Roche has one of the best long-term growth profiles in the Big Pharma space -
Elan Continues To Make Baffling Strategic Decision
Elan seems to be set on wasting the Tysabri windfall instead of returning it to shareholders -
After A Big Rally, Pfizer Might Need Some Rest
A big rally has brought Pfizer back to fair value.
Free Annual Reports